StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) Climbs 1.6% After Upgrade, Phase 3 STELLAR Trial of Sotatercept Meets Primary Endpoint
October 10, 2022 7:22 AM
Merck (NYSE: MRK) Climbs 1.6% After ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Trader Talk
Next Articles
Merck (MRK) Shares Rally, Analyst Believes Data Supports Approval of Statercept in PAH
October 10, 2022 11:02 AM
Merck (MRK) Reports Positive Top-line Results from Pivotal Phase 3 STELLAR Trial of Sotatercept
October 10, 2022 6:46 AM
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
October 10, 2022 6:45 AM
UPDATE: Guggenheim Upgrades Merck (MRK) to Buy
October 10, 2022 6:42 AM
